Correlation of serum biomarkers with clinical severity and mucosal inflammation in Chinese ulcerative colitis patients

Journal of Digestive Diseases

Volumn 9, Issue 4, 2008, Pages 219-224

  Lok, Ka Ho ^a   Ng, Chi Ho ^a   Hung, Hiu Gong ^a   Li, Kam Fu ^a   Li, Kin Kong ^a   Szeto, Ming Leung ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Biomarkers; C reactive protein; Clinical; Correlation; Erythrocyte sedimentation rate; Mucosal inflammation; Ulcerative colitis

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEMOGLOBIN;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FISHER EXACT TEST; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; KRUSKAL WALLIS TEST; LEUKOCYTE COUNT; MALE; MUCOSA INFLAMMATION; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROCTITIS; RANK SUM TEST; RELAPSE; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; ULCERATIVE COLITIS;

ADULT; AGED; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; FEMALE; GASTRIC MUCOSA; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 55149109705     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2008.00350.x     Document Type: Article

References (18)

1. Wang YF, Zhang H, Ouyang Q. Clinical manifestation of inflammatory bowel disease: East and West differences. J Dig Dis 2007; 8: 121-7.
2. Nielsen O, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 359-67.
3. Rutgeerts P, Colombel J, Enns R et al. Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn's disease therapy -1 (ENACT -1). Gut 2003; 52: A239.
4. Sandborn W, Feagan B, Radford-Smith G et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: A randomised, double blind, placebo controlled trial. Gut 2004; 53: 1485-93.
5. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic or unnecessary toys? Gut 2006; 55: 426-31.
6. Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol 2005; 21: 408-13.
7. Lok KH, Hung HG, Ng CH et al. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: Experience from a single center in Hong Kong. J Gastroenterol Hepatol 2007; 23: 406-10.
8. Lok KH, Hung HG, Ng CH, Li KK, Li KF, Szeto ML. The epidemiology and clinical characteristics of Crohn's disease in the Hong Kong Chinese population: Experiences from a regional hospital. Hong Kong Med J 2007; 13: 436-41.
9. Kornbluth A, Sachar D. Ulcerative colitis practice guidelines in adults (update). American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85.
10. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: Controversies, consensus and implications. Gut 2006; 55: 749-53.
11. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170: 2-6.
12. Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, radiographic, and endoscopic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-12.
13. Gross V, Andus T, Caesar I, Roth M, Schölmerich J. Evidence for continues stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514-9.
14. Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S, Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 1986; 8: 647-50.
15. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol 2002; 8: 158-61.
16. Jiang L, Xia B, Li J et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006; 12: 212-7.
17. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50-4.
18. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 176-80.